VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Anfield Energy Inc. (“Anfield” or the “Company”) (TSX.V: AEC; NASDAQ: AEC; FRANKFURT: 0AD) is pleased to announce that the Colorado Division of Reclamation, Mining and Safety (“DRMS” or the “Division”) has concluded its review of the 112d-1 Hard Rock Reclamation Permit Application for the Company’s past-producing JD-8 uranium and vanadium mine (the “JD-8 Mine” or “JD-8”) in Montrose County, Colorado, filed by Anfield’s operating subsidiary, Highbury Resources Inc. (“Highbury”), under File No. M-2025-056. By decision letter dated September 29, 2026, the Division approved a permit area and affected area of 28.30 acres and set the required financial warranty (reclamation surety) at US$620,000. The reclamation permit will be issued once the Division receives and verifies Highbury’s financial and performance warranty.

With the Division’s review complete, the focus turns to Federal review under the U.S. Department of Energy (“DOE”) Uranium Leasing Program, which is currently advancing. On September 29, 2026, DOE notified the Company that it had reviewed Highbury’s draft Environmental Assessment (“EA”) template for the JD-8 Mine Plan and found it acceptable, allowing the National Environmental Policy Act (“NEPA”) review of the JD-8 Mine Plan to proceed. Subject to permit issuance, DOE Mine Plan approval and remaining operational readiness work, Anfield continues to target a restart of uranium and vanadium production at JD-8 by the end of the second quarter of 2027.

Separately, Anfield has responded to the U.S. National Nuclear Security Administration (“NNSA”) request for information regarding the potential acquisition of approximately 4 million pounds of unobligated domestic uranium per annum to support national-security fuel-cycle requirements.

Ken Mushinski, Anfield Chairman commented: “This is a major step toward restarting Anfield’s production in 2027, and it is especially meaningful for me personally, as a former President of Cotter Corporation, the previous owner of this significant resource. Given my first-hand knowledge of and experience with the JD-8 resource, legacy mining and permitting preservation, I have genuine confidence in the current permitting and restart work being accomplished by Anfield today. We look forward to becoming a major contributor to U.S. uranium and vanadium production, and this decision is another significant step toward that goal.”

Corey Dias, Anfield CEO, stated, “The completion of the Division’s review is a defining milestone for JD-8 and for our Colorado strategy. We now have a clear, defined path to permit issuance, and DOE’s acceptance of our Environmental Assessment template shows the federal process is also poised for progress. JD-8 is a past-producing mine with existing underground workings and is intended to be another spoke feeding Shootaring, similar to Velvet-Wood. With term uranium prices at nominal record levels, we believe that advancing a permitted, U.S. conventional mine toward production will allow Anfield to take full advantage of current market conditions.”

Once the DRMS permit is issued and DOE approval is received, the Company expects to proceed with mobilization, underground rehabilitation and restart activities. The existing JD-7 mine infrastructure will be used as the operations base for the Monogram Mesa Mine Complex, which includes the JD-8 mine.

Because the application is no longer contested, the Division proceeded to its decision, and the JD-8 application will not be on the agenda for the Colorado Mined Land Reclamation Board’s regular October 14–15, 2026 meeting.

JD-8 in Anfield’s Hub-and-Spoke Strategy

JD-8 is located approximately 11 miles west of Naturita, Colorado, on approximately 28.3 acres within DOE Uranium Leasing Program lease tracts. It is a past-producing conventional underground uranium and vanadium mine and a key asset within Anfield’s Monogram Mesa Mine Complex. JD-8 was the last of the historic Cotter Corporation mines to suspend operations, in 2006, due to market conditions. The restart plan uses conventional underground mining methods and leverages the existing underground workings.

Anfield’s PEA contemplates the Shootaring Canyon Mill as a central processing hub with a target capacity of 1,000 tons per day, fed by Velvet-Wood (Utah), Slick Rock (Colorado) and six West Slope mines, including JD-8. The PEA estimates average annual production of approximately 1.3 million pounds of U₃O₈ and 6.4 million pounds of V₂O₅ over a 15-year mine life, with a pre-tax net present value (8% discount) of US$606 million and pre-tax internal rate of return of 106% (post-tax NPV of US$533 million and IRR of 97%), based on US$100 per pound uranium and US$9 per pound vanadium.¹ Velvet-Wood remains the Company’s first mine advancing toward production; JD-8 and Slick Rock are intended to be the next mines in the hub-and-spoke model. The potential future addition of some, or all, of the Company’s fifteen DOE lease tracts not included in the PEA represents upside to the production pipeline. Following JD-8, Anfield intends to advance permitting at JD-7 and Slick Rock.

Uranium Market

Uranium markets remain strong. According to industry-average prices published by Cameco Corporation (based on UxC and TradeTech data), the long-term uranium price closed August 2026 at US$96.50 per pound, above its 2007 peak in nominal terms, and the month-end spot price was US$89.68 per pound. The United States consumes nearly 50 million pounds of uranium annually yet produces only a small fraction domestically. Anfield believes that permitted, past-producing conventional mines that can feed a licensed U.S. mill are well placed in this market.

Growing U.S. Government Demand for Domestic, Unobligated Uranium: Consistent with that view, Anfield submitted a response to a Request for Information titled “NNSA Uranium Acquisition” (Notice No. 89233126RNA000332), for which responses were due September 15, 2026. In the RFI, NNSA described a long-term, steady-state requirement of approximately 4 million pounds per year of unobligated U.S.-origin U₃O₈ (approximately 1,500 metric tons of uranium as UF₆), identified 2030 as the earliest opportunity to begin defense mission-specific procurements, and stated that it intends to procure from the domestic uranium recovery industry, including conventional uranium mills. The RFI is market research and not a solicitation or commitment to purchase. Separately, on August 26, 2026, the U.S. Army announced that it expects more than 20 nuclear microreactors to be built and operated at U.S. military installations under its Janus Program. Anfield believes that its U.S. conventional mines, including JD-8, together with its licensed Shootaring Canyon Mill, are well positioned to help meet growing demand for domestic, U.S.-origin uranium.

Qualified Person

Douglas L. Beahm, P.E., P.G., is the Company’s qualified person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) and has reviewed, verified and approved the scientific and technical information contained in this news release. Mr. Beahm is not independent of the Company, as he is the Company’s Chief Operating Officer. [Doug to confirm sign-off.]

Mineral Resources and PEA Cautionary Statement

Mineral resources are not mineral reserves and do not have demonstrated economic viability. The PEA is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. There is no certainty that the PEA will be realized. The JD Mines mineral resource estimate is set out in the technical report titled “US DOE Uranium/Vanadium Leases JD-6, JD-7, JD-8 and JD-9, Montrose County, Colorado, USA, Mineral Resource Technical Report, National Instrument 43-101,” dated effective April 10, 2022, which the PEA’s qualified persons reviewed and deemed to remain valid and effective.¹

Production Decision

The Company’s decision to advance development and permitting of the JD-8 uranium and vanadium mine is based on historical production data and analysis of available technical information, and not on a feasibility study of mineral reserves demonstrating economic and technical viability. As a result, there is increased uncertainty and a higher risk of economic or technical failure associated with that decision.

About Anfield

Anfield Energy is a uranium and vanadium development and near-term production company committed to becoming a significant supplier of energy-related fuels through sustainable, efficient growth of its U.S.-based assets. The Company’s flagship asset is the Shootaring Canyon Mill in Utah, one of only three licensed, permitted, and constructed conventional uranium mills in the country. Anfield’s portfolio includes the advanced Velvet-Wood project (Utah) and other conventional uranium-vanadium assets in Utah, Colorado, Arizona, and New Mexico. All of Anfield’s assets are located in the United States, positioning the Company to help meet America’s growing nuclear fuel needs.

On behalf of the Board of Directors
ANFIELD ENERGY INC.
Corey Dias, Chief Executive Officer

Contact:
Anfield Energy, Inc.
Corporate Communications
604-669-5762
contact@anfieldenergy.com
www.anfieldenergy.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. All statements, other than statements of historical facts, are forward-looking statements. Generally, forward-looking statements can be identified by the use of terminology such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes”, “target” or variations of such words, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “occur” or “be achieved”. Forward-looking statements in this release include, but are not limited to, statements regarding the submission and acceptance of the financial and performance warranties for JD-8 and the timing thereof; the issuance of the JD-8 reclamation permit by DRMS; the completion of DOE’s NEPA review and DOE approval of the JD-8 Mine Plan; mobilization and the targeted restart of production at JD-8 by the end of the second quarter of 2027; the use of JD-7 infrastructure as an operations base; the shipment of JD-8 ore to the Shootaring Canyon Mill and JD-8’s role in the Company’s hub-and-spoke strategy; the sequencing of Velvet-Wood, JD-8 and Slick Rock; plans to advance permitting at JD-7 and Slick Rock; the results of the PEA, including estimated production, NPV, IRR and capital costs; the potential addition of the Company’s remaining DOE leases; and uranium market conditions.

Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance and opportunities to differ materially from those implied by such forward-looking statements, including, among other things: the risk that the Company is unable to post the required financial warranty in the time or form contemplated; the risk that DRMS does not issue the permit when anticipated or at all, or imposes additional requirements; the risk that DOE’s NEPA review or Mine Plan approval is delayed, requires additional information, or is not obtained; the need for additional federal, state or local permits or approvals; the ability of the Company to obtain financing; construction, contractor, mobilization and operating risks, including risks related to the condition of the underground workings; the risk that the PEA results are not realized; fluctuations in the prices of uranium and vanadium; the need to comply with environmental and governmental regulations in Canada and the United States; competition; and other risks and uncertainties set forth in the Company’s annual information form, management’s discussion and analysis and other disclosures of risk factors filed on SEDAR+ at www.sedarplus.ca. Although the Company believes that the information and assumptions used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by applicable law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

¹ See the June 18, 2026 news release and the technical report titled “The Shootaring Canyon Mill and Tributary Mines, Utah and Colorado, USA, Preliminary Economic Assessment,” dated effective May 4, 2026, available on the Company’s SEDAR+ profile.

Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials

First patient treated in new clinical trial underway at Roswell Park

Treatment is designed to avoid pre-infusion chemotherapy and its side effects

GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors

BUFFALO, N.Y. and SOMERVILLE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Roswell Park Comprehensive Cancer Center (“Roswell Park”) and Generate Biomedicines, Inc. (“Generate”) today announced that the first patient has been dosed in a first-in-human clinical trial evaluating GB-5267, an investigational, autologous IL-18 armored CAR T-cell therapy designed to overcome key barriers that have limited the success of cellular therapies in ovarian cancer and other solid tumors. GB-5267 targets the antigen MUC16, which is over-expressed by more than 80% of ovarian tumors and helps them grow, spread, and hide from the immune system. The trial is recruiting patients whose disease has returned after treatment or does not respond to platinum-based chemotherapy, the standard first-line treatment.

Led by Principal Investigator Emese Zsiros, MD, PhD, FACOG, Chair of Gynecologic Oncology at Roswell Park, the phase 1 clinical trial (NCT07489287) will evaluate the safety and tolerability of GB-5267.

Each patient’s T cells, immune cells capable of killing cancer cells, will be collected, genetically engineered, and expanded in Roswell Park’s GMP Engineering & Cell Manufacturing Facility before being returned to the patient to target an attack against the tumor.

While T-cell therapies have revolutionized the treatment of blood cancers, leading to long-term remission or even cure for many patients, solid tumors — cancers that grow in organs or tissue — have posed more of a challenge. That’s because the tumor’s microenvironment, a protective cocoon that surrounds it, prevents immune cells from entering the tumor or even being able to recognize it. But investigators believe they have found a way around that roadblock.

“We’re armoring the T cells with IL-18, a cytokine that will help protect them from the suppressive microenvironment of the solid tumor,” explains Marco Davila, MD, PhD, Senior Vice President and Associate Director for Translational Research at Roswell Park. Dr. Davila co-developed some of the first CAR T-cell therapies and has played a key role in refining them.

“Because ovarian cancer spreads through the peritoneal cavity, the CAR T-cell therapy will be delivered in two ways: intravenously and into the peritoneal cavity,” adds Dr. Zsiros. “This strategy is designed to concentrate the immune response where it is needed, without the toxicity of high-dose chemotherapy.”

GB-5267 was engineered by Generate with AI through the design and evaluation of CAR architectures at scale based on how T cells actually behave, rather than relying on binding affinity as a proxy for performance. GB-5267 was designed to optimize three interdependent functions required for CAR T-cell performance in solid tumors:

  • Potency, the ability to kill MUC16-expressing tumor cells
  • Proliferation, the ability to expand into a larger T-cell population
  • Persistence, the ability to remain active over time in a suppressive tumor microenvironment

“Recognizing a tumor antigen is only one part of the challenge. In solid tumors, a CAR T cell that kills but does not expand or persist is a partial solution. GB-5267 was computationally designed with potency, proliferation, and persistence to maintain activity in a suppressive tumor microenvironment. Dosing the first patient begins the clinical test of whether that function-first approach behaves in patients as intended,” says Dinesh de Alwis, PhD, Senior Vice President and Head of Clinical Drug Development at Generate Biomedicines.

Unlike many CAR T-cell approaches, this study will not require lymphodepletion, which uses chemotherapy to reduce the patient’s original immune cells to provide more space for the new cells. That means patients will not be exposed to the side effects associated with chemotherapy.

Typically, ovarian cancer is treated with surgery followed by platinum-based chemotherapy. When the disease recurs, it often no longer responds to chemotherapy, at which point it is very difficult to treat, with few options. The five-year relative survival rate for the disease is only 51.6%.

“CAR T-cell therapy has transformed outcomes in blood cancers,” says Dr. Zsiros. “With this clinical trial, we are working to bring that progress to people with ovarian cancer.”

Research leading to this clinical trial was made possible in part by donations to the Roswell Park Alliance Foundation’s Igniting Cancer Breakthroughs campaign and through events like Ride for Roswell.

For information about this ongoing and currently enrolling Phase 1 study or other clinical trials at Roswell Park, please call 1-800-ROSWELL (1-800-767-9355) or email ASKRoswell@RoswellPark.org.

About Roswell Park
From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. The Roswell Park team of 4,000+ makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Rated “Exceptional” by the National Cancer Institute, Roswell Park, founded in 1898, was one of the first NCI-designated comprehensive cancer centers in the country and remains the only one in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email ASKRoswell@RoswellPark.org.

About GB-5267
GB-5267 is an investigational, autologous IL-18-armored CAR T-cell therapy engineered by Generate with AI for the treatment of solid tumors, initially focused on platinum-resistant ovarian cancer. The program applies a function-first design approach intended to optimize potency, proliferation, and persistence, three CAR T-cell behaviors relevant to activity in solid tumors. GB-5267 is being evaluated in a first-in-human phase 1 clinical trial (NCT07489287) led by Roswell Park Comprehensive Cancer Center.

About Generate Biomedicines Inc.
Generate (NASDAQ: GENB) is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, and medicine, advancing a new era of programmable biology to engineer better drug candidates for patients, faster. The Generate Platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address historically undruggable and hard-to-drug targets, as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded in 2018, Generate is leading a fundamental shift from drug discovery to drug generation. Learn more at www.generatebiomedicines.com or follow us on X, LinkedIn, and YouTube.

Cautionary Note Regarding Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding Generate’s expectations relating to the advancement of GB-5267; the initiation, design, conduct, timing, progress, and results of its Phase 1 clinical trial; the potential safety, tolerability, and therapeutic benefits of GB-5267; and the expected benefits and potential of The Generate Platform. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions.

These forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, but not limited to, risks and uncertainties related to Generate’s ability to successfully develop and obtain regulatory approval for its drug candidates; the initiation, design, progress, timing, and results of preclinical studies and clinical trials; Generate’s ability to obtain, maintain, and enforce intellectual property protection; Generate’s dependence on third parties for the manufacture and development of its drug candidates; the impact of competitive products and technologies; Generate’s ability to replicate results from earlier preclinical studies or clinical trials in current or future clinical trials; Generate’s ability to demonstrate that its drug candidates are safe and effective for their proposed indications; Generate’s ability to obtain additional capital to fund its operations; and general economic, industry, and market conditions.

Additional information on these and other risks and uncertainties that could affect Generate’s business, financial condition, and results of operations is included in Generate’s filings with the Securities and Exchange Commission, including its Quarterly Reports. The forward-looking statements in this news release are made as of the date hereof, and Generate undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this news release, except as required by applicable law.

Roswell Park Media Contact
Jane Rose
Jane.rose@roswellpark.org
716-845-4919

Generate Media Contact
Megan McLaughlin
pr@generatebiomedicines.com

Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company’s sterile placental allograft, micronized wound care, and umbilical cord extract technologies

POMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the United States Patent and Trademark Office (USPTO) has issued one patent and three notices of allowance for additional patent applications and the Mexican Institute of Industrial Property (IMPI) has issued one notice of allowance for additional patent applications.

The newly issued patent and allowed applications broaden BioStem’s intellectual property portfolio across its placental and umbilical cord tissue technologies in wound care, surgical and joint applications.

U.S. Patent No. 12,648,969: STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF

The application is directed to human placental allografts having various uses including treatment of wounds and diabetic foot ulcers.

U.S. Patent Application No. 19/660,625: STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF (allowance mailed September 25, 2026)

The application is directed to treating wounds with human placental allografts.

U.S. Patent Application No. 19/681,608: MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM HUMAN UMBILICAL CORD TISSUE AND INTACT AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEEN (allowance mailed August 19, 2026)

The application is directed to combination products having micronized human umbilical cord tissue and micronized human amnion-chorion tissue and methods of wound treatment using the same.

U.S. Patent Application No. 17/873,383: UMBILICAL CORD EXTRACT FOR JOINT CUSHIONING AND LUBRICATION (allowance mailed August 18, 2026)

The application is directed to compositions and methods for the treatment of joint inflammation.

Mexican Patent Application No. MX/a/2025/000164: STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF

The application is directed to human placental allografts having various uses including treatment of wounds and diabetic foot ulcers.

“Investing in our intellectual property remains a priority for BioStem, and this patent and four allowances reflect the progress of that effort,” said Jason Matuszewski, Chair and CEO of BioStem Technologies. “We plan to continue to commit resources to expanding and defending our patent estate, both in the U.S. and internationally, so that the technologies we develop stay protected as we grow our product offerings for clinicians and their patients.”

The issued patent and allowed applications further expand BioStem’s growing intellectual property portfolio, which includes more than 100 patents and patent applications worldwide. BioStem continues to invest in innovation across placental and umbilical cord tissue processing, preservation technologies, and allograft designs as it develops next-generation products for wound care, surgical and joint applications.

BioStem’s proprietary processing technologies are designed to optimize preservation of the innate structural and biological characteristics of perinatal tissues, supporting their use in a variety of clinical applications, including surgical and wound care procedures.

About BioStem Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.

Forward-Looking Statements:
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s plans to expand and defend its patent portfolio, grow its product offerings, and invest in innovative technologies.

Forward-looking statements with respect to strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; the Company’s ability to obtain financing on terms acceptable to it, or at all; the impact of any changes in applicable laws or regulations; the Company’s accounts receivable collection risk and concentration; the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and the possibility that the Company may be adversely affected by other general economic, business, and/or competitive factors. There may be additional risks about which the Company is presently unaware of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company undertakes no duty to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.

Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: pr@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Philip Trip Taylor, Gilmartin Group
ir@biostemtech.com

Thras Moraitis Sets Integration, Execution and Growth Priorities

STILLWATER, Okla., Oct. 01, 2026 (GLOBE NEWSWIRE) — USA Rare Earth (Nasdaq: USAR) (the “Company”), a rare earth, critical minerals and advanced materials company, today announced the completion of its previously disclosed CEO succession plan. Thras Moraitis, who was previously President of USA Rare Earth, has assumed the CEO position and will focus on integrating the Company’s rare-earth businesses, strengthening execution and reliably serving customers seeking secure supplies of critical materials.

“We have assembled the capabilities needed to compete across the rare-earth value chain across multiple countries,” said Thras Moraitis, CEO of USA Rare Earth. “Our immediate priority is to bring these businesses together, establish clear accountability and execute reliably for customers. A relentless focus on implementation will be central to delivering value for our investors, customers, government partners and host communities.”

The Company has organized its operations into three business units designed to support faster decision-making, accountability and disciplined execution while maintaining coordination across the platform: Upstream, covering mining, processing and separation; Midstream, covering metals, alloys and powders; and Downstream, covering magnets and derivative products. Moraitis will serve as head of Upstream, Chaitan Kansal will lead Midstream, and David Bushi will lead Downstream. The Company’s priorities include operational performance, customer delivery, capital discipline and the continued development of a secure, Western-aligned rare-earth products supply chain.

“Today marks an important transition for USA Rare Earth as Thras Moraitis assumes the role of Chief Executive Officer,” said Mike Blitzer, Executive Chairman of USA Rare Earth. “On behalf of the Board, I want to thank Barbara Humpton for her leadership and contributions in helping to build the foundation of our rare-earth platform.

“Thras brings the experience, judgment and focus needed to lead the Company through its next phases of development and to pursue further value accretive opportunities. The organizational framework which Thras has established creates the conditions for accountability and transparency within our operating units so that they can rapidly integrate, scale and deliver for our customers.”

Following the close of the combination with Serra Verde, USA Rare Earth is positioned across all key stages of the rare-earth supply chain. The platform includes Serra Verde’s mine and processing facility in Brazil, the Round Top heavy rare earth project in Texas, advanced processing and separation capabilities in Wheat Ridge, Colorado, Less Common Metals’ metals and alloys operations in the United Kingdom, and the Company’s expanding magnet production in the United States. Pending closing of its previously-announced transaction, USA Rare Earth’s shareholding in Carester will provide access to world-class heavy rare-earth separation engineering capabilities and related intellectual property.

Demand for rare-earth metals and magnets is increasing across energy, semiconductors, medical technology, defense and mobility, while governments are accelerating efforts to diversify critical-mineral supply chains. USA Rare Earth aims to be a preferred partner to governments and industrial customers seeking reliable, secure alternative supply chains.

Investor Contact

J.B. Lowe, CFA
Vice President, Investor Relations
USA Rare Earth, Inc.
ir@usare.com

Media Contact

Collected Strategies
USAR-CS@collectedstrategies.com

About USA Rare Earth, Inc.

USA Rare Earth, Inc. (Nasdaq: USAR) is building a fully integrated rare-earth and permanent-magnet value chain across the United States, Brazil and the United Kingdom. Through its ownership of Less Common Metals (LCM), one of the world’s leading producers of rare-earth metals and alloys, its development of magnet manufacturing capacity in Stillwater, Oklahoma, its Pela Ema mine in Brazil and the Round Top deposit in Texas, USA Rare Earth is pursuing capabilities across the value chain from mining to metal-making, alloy production and neodymium magnet manufacturing. USA Rare Earth is establishing a secure, Western-aligned supply of materials essential to the aerospace and defense, semiconductor, energy, data center, physical AI, mobility, healthcare and industrial sectors. For more information, visit www.usare.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those relating to expected access to heavy rare-earth separation knowhow following USA Rare Earth’s announced investment in Carester SAS and other statements regarding USAR’s expectations for future development, operations, strategies, transactions and financial performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Words such as “anticipate,” “can,” “continue,” “could,” “growth,” “may,” “might,” “plan,” “potential,” “project,” “propose,” “should,” “target,” “vision,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements are subject to risks and uncertainties and potentially inaccurate assumptions that could cause actual results to differ materially from USA Rare Earth’s expectations, including without limitation: risks that USA Rare Earth may not realize the anticipated benefits of its combination with Serra Verde or its proposed and prior acquisitions, including expected synergies, financial performance, estimated earnings before interest, taxes, depreciation and amortization and, in the case of Serra Verde, integration of operations, on the anticipated timeline or at all; risks that the proposed transaction with Carester SAS may not be consummated on its anticipated timeline or at all; potential delays in the optimization and commissioning program and the Phase II expansion at the Pela Ema facility; political, economic, regulatory, tax, currency and other risks associated with Serra Verde’s operations in Brazil and Switzerland; physical climate risks related to the Pela Ema mine; the assumption of the Offtake Agreement and substantial indebtedness under Serra Verde’s Retained Finance Agreement, in each case which contains restrictive covenants and other requirements that could adversely affect the combined company’s financial flexibility and operations; risks that the Offtake Agreement is terminated or ceases to be in full force and effect or that the counterparty to the Offtake Agreement is insufficiently capitalized, including as a result of a failure to finalize definitive debt financing arrangements within the timeframes contemplated by the Offtake Agreement; the ability of USA Rare Earth’s Stillwater magnet manufacturing facility to generate revenue and the ability of USA Rare Earth’s planned Blacksburg facility to commence commercial operations on the timing and with the production capacity anticipated or at all; USA Rare Earth’s limited operating history; USA Rare Earth’s ability to commercially extract minerals from the Round Top deposit on its anticipated timeline or at all; differences between planned and actual recovery and yield rates; risks that USA Rare Earth may experience delays, unforeseen expenses, increased capital costs, and other complications while developing its projects; USA Rare Earth’s ability to raise necessary capital on acceptable terms or at all; potential dilution to existing stockholders and adverse effect on USA Rare Earth’s stock price if it issues additional common stock or equity-linked securities; the volatility of USA Rare Earth’s stock price; the availability of rare earth oxide, metal feedstock and other materials, utilities (including power and water) and equipment in quantities and prices that allow USA Rare Earth to develop and commercially operate its Stillwater facility and other facilities; USA Rare Earth’s ability to meet individual customer specifications and produce a consistently high quality product; potential supply chain, logistics or product delivery disruptions; any delays in obtaining or renewing permits and licenses; any changes in royalty rates or the imposition of new royalties; risks associated with community relations; fluctuations in demand for and prices of neo magnets, rare earth elements and USA Rare Earth’s other products, including without limitation as a result of dumping, predatory pricing and other tactics by USA Rare Earth’s competitors or state actors or the overall competitive environment; USA Rare Earth’s ability to achieve positive cash flow or profitability or the ability to access cash flow within its corporate structure due to restrictions contained in its financing agreements; USA Rare Earth’s ability to convert current commercial discussions and/or memorandums of understanding with customers for the sale of its neo magnets and other products into definitive orders; USA Rare Earth’s dependence, in part, on the growth of existing and emerging uses for neo magnets; the risk that additional manufacturing, refining and mining competitors could result in a reduction in revenue; geopolitical developments or disruptions, such as changes in the political environment, export/import or environmental policy of the People’s Republic of China, the United States or other countries in which USA Rare Earth operates or sells products or otherwise; USA Rare Earth’s designation on an export control list by China which has had and is expected to continue to have an adverse impact on its ability to source key raw materials and supplies from China; war, terrorism, natural disasters or public health emergencies; USA Rare Earth’s ability to retain or recruit key personnel; environmental, health and safety regulations; the receipt of funding from the U.S. Department of Commerce is subject to the achievement of milestones which may not be achieved on the expected timeline or at all; and USA Rare Earth’s ability to comply with requirements for federal, state and local government incentives and financing.

Additional risks and detailed information regarding factors that may cause actual results to differ materially has been and will be included in USA Rare Earth’s filings with the SEC, including USA Rare Earth’s most recently filed Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q and subsequent filings. Any forward-looking statements speak only as of the date of this press release (or such other date as is specified in such statements), and USA Rare Earth undertakes no obligation to update any forward-looking statements as a result of new information or future events or developments.

The sale brings approximately US$15.0 million to support working capital, R&D, new corn varieties, and market expansion, while the five-year lease-back maintains supply stability

BEIJING, Oct. 01, 2026 (GLOBE NEWSWIRE) — Origin Agritech Limited (NASDAQ: SEED) (“Origin” or the “Company”), a leading Chinese agricultural technology company, today announced that its indirect subsidiary, Beijing Origin Agriculture Limited (“Beijing Origin”), has entered into an equity transfer agreement (the “Agreement”) to sell its 70.5184% equity interest in Xinjiang Originbo Seed Limited (“Xinjiang Originbo”), the Company’s principal corn seed production and processing base (the “Base”), to Hunan Xindaxin Limited (“Hunan Xindaxin”) for RMB 108 million (approximately US$15.0 million). Beijing Origin has also signed a five-year lease for all the buildings, machinery, equipment, and other assets comprising the Base, running from October 1, 2026, to September 30, 2031. The lease-back preserves the Company’s core business operations: seed production and sales at the Base continue to be recorded by Beijing Origin; overall management of the Base remains stable; and operating personnel are unchanged, except for core finance and risk control roles.

Origin decided to sell the Base to optimize its asset structure: the Company replaces ownership of a capital-intensive facility with a lease, and the capital tied up in the facility becomes RMB 108 million of scheduled proceeds. The Base sits in one of China’s most important corn seed production regions and re-emerged as one of China’s top-tier seed processing plants after its 2025 upgrade, with fully automated lines covering dehusking, drying, threshing, cleaning, precision sorting, coating, and packaging. It has processed Origin’s own hybrids and provided seed production services to third parties. Under the lease, Origin retains use of the lines and the team that runs them for RMB 4.0 million per year. The Company intends to apply the proceeds to working capital, research and development (R&D), the development and purchase of new corn varieties, and market expansion, following its August 2026 opening of the Southwest R&D Center in Guizhou and its acquisition of exclusive nationwide commercialization rights to the machine-harvest corn hybrid Zhongdan 6202.

“The sale substantially improves the Company’s liquidity and lets the team focus on the recovery of sales of our new variety portfolio, the expansion of our sales and service infrastructure, and our R&D programs, while the lease-back keeps our seed supply secure and efficient,” said Weibin Yan, Chief Executive Officer of Origin Agritech. “As I begin my third year as CEO, we are leading the Company into the ‘Standing Up’ stage of our multi-year strategic plan, and this transaction paves the way through this critical period.”

Transaction Terms

Under the Agreement, dated September 8, 2026, the transfer price of RMB 108 million was determined with reference to a valuation report issued by Xinjiang Woshi Asset Appraisal Firm (General Partnership) with a valuation benchmark date of June 30, 2026. Hunan Xindaxin will pay the full purchase price in four installments: RMB 18 million by December 31, 2026, and RMB 30 million by each of February 28, April 30, and June 30, 2027. RMB 11.39 million that Beijing Origin owed to Hunan Xindaxin at signing has been applied against the first installment, leaving RMB 6.61 million of that installment payable in cash. In total, RMB 96.61 million (approximately US$13.4 million) is payable in cash through June 30, 2027. Beijing Origin retains legal title to the equity interest until the full price has been paid.

Lease Terms

Under the Seed Production Base Asset Lease Agreement, signed on September 30, 2026, Beijing Origin leases from Xinjiang Originbo all 506 asset items comprising the Base: 70 buildings and structures, including the dehusking, drying, threshing, and cleaning workshops, silos, warehouses, drying yards, and power facilities; 367 items of machinery and equipment, including the dehusking, drying, threshing, and cleaning production lines; 49 electronic devices; 18 vehicles and other transportation equipment; and two other items. The term is five years, from October 1, 2026, to September 30, 2031. Annual rent is RMB 4.0 million (approximately US$0.6 million) and covers only the use of the assets; Beijing Origin bears utilities, labor, maintenance consumables, and routine maintenance, while repairs arising from natural aging of the assets are for Xinjiang Originbo’s account. Beijing Origin may renew by written application at least 30 days before expiry and holds a right of first refusal on renewal on equal terms.

Operational Continuity

The lease-back of the Base does not affect the Company’s core business operations. The Base’s fully automated processing line continues to process Origin’s seed, and seed production and sales revenue generated at the Base continue to be recorded by Beijing Origin. Overall management of the Base remains stable. Apart from core finance and risk control personnel appointed by Hunan Xindaxin under the Agreement, operational personnel at the Base remain unchanged. The five-year term secures Origin’s use of the Base through September 2031.

Related-Party Transactions and Approval

Mr. Yan, who is also the legal representative of Beijing Origin, holds approximately 9.75% of the equity of Hunan Xindaxin, which appoints the directors and senior management of Xinjiang Originbo under the Agreement. The equity transfer and the lease are therefore related-party transactions. The Audit Committee of Origin’s Board of Directors, composed entirely of independent directors, reviewed and approved both agreements, and Mr. Yan recused himself from the Board’s deliberations and vote. The Company furnished these agreements to the U.S. Securities and Exchange Commission (the “SEC”) as exhibits to a Form 6-K report yesterday.

About Origin Agritech Limited

Origin Agritech Limited, founded in 1997 and headquartered at the Origin R&D Center in Songzhuang, Tongzhou, Beijing, is a leading Chinese agricultural technology company. In crop seed biotechnology, Origin Agritech’s phytase corn was the first transgenic corn to receive a Biosafety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and Bt (pest resistance) traits. For further information, please visit the Company’s website at www.originagritech.com. The Company also maintains an X account to update investors on Company and industry developments, available at https://x.com/origin_agritech.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the payment of the transfer price and the completion and registration of the equity transfer, the continuity of operations and personnel at the Base, the performance and renewal of the lease, the Company’s intended use of proceeds, and the accounting treatment and financial effect of the transactions. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “will,” “would,” “target,” and similar expressions identify forward-looking statements. These statements involve known and unknown risks and uncertainties — including the risk that Hunan Xindaxin does not pay the transfer price when due, the risk that the lease is terminated early or is not renewed on acceptable terms or at all upon its expiry on September 30, 2031, delays in the registration of the equity transfer, disruption of the Company’s operations at the Base, competitive variety introductions, pricing pressure in the Chinese seed market, regulatory and agricultural policy developments in China, currency fluctuation, and the Company’s ability to fund and execute the plans described above — which may cause actual results to differ materially from those expressed or implied. Forward-looking statements are not guarantees of future performance. Origin Agritech undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by securities and other applicable laws.

For more information, please contact:

Origin Agritech Limited Contact:

Kate Lang (Mandarin/English)
Director of Investor Relations
Phone: +86 186-1839-3368
Email: bing.lang@originseed.com.cn

Investor Relations Contact:

Matthew Abenante, IRC
President
Strategic Investor Relations LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com

Baltimore, MD, Oct. 01, 2026 (GLOBE NEWSWIRE) — The signs of poor metabolic health can be difficult to analyze without a clinical framework. Trilivy™, a science-backed, coach-guided metabolic health system, points to five frequently overlooked patterns adults can recognize before noticeable weight and energy fluctuations. 

“Few people encounter a working definition of metabolic health before a diagnosis makes it necessary. Until then, progress is often measured by body weight, a number that leaves out visceral fat and lean mass entirely. This reduces an individual’s ability to better understand the state of their metabolic health,” said Satya Jonnalagadda, PhD, MBA, RD, Vice President of Scientific & Clinical Affairs at Trilivy, a registered dietitian with more than two decades of experience spanning chronic disease management and medical nutrition.

Sign 1: Visceral Fat Is Rising Even When Body Weight Is Stable

Body weight alone is not a reliable indicator of changes in the deeper fat surrounding the organs. Visceral fat releases inflammatory molecules and hormones that affect insulin sensitivity and cardiovascular risk, which is why waist circumference is often a more useful early indicator than total body weight alone. 

Sign 2: Lean Mass Loss Alongside Any Attempted Weight Loss

Without a framework designed to preserve lean mass during weight loss, body composition changes may affect how the metabolism functions over time, a factor that structured programs are specifically designed to address. 

Sign 3: Energy Has Shifted Into Post-meal Crashes and Afternoon Slumps
Healthy metabolic function produces steady energy across the day. When insulin sensitivity and meal timing fall out of sync, energy becomes erratic, leading to sharper post-meal crashes and late-afternoon fatigue. 

Sign 4: Weight Regain and Return to Old Habits
The cyclical pattern of structured plan, early progress, plateau, partial regain, and a new program next quarter is one of the signs of poor metabolic health hiding in plain sight. It signals that the underlying dysfunction was not addressed, only its most visible sign. 

Sign 5: Doing Everything “Right” Has Stopped Producing Change

In the U.S., 80% of adults lack an understanding of how metabolic health affects their overall well-being.¹ Without a framework built around small, repeatable habits across daily life, willpower alone often isn’t enough to sustain change, since the underlying patterns driving metabolic dysfunction go unaddressed.

How Trilivy’s Metabolic Synchronization® and MetaVantage Reset Formula Target These Signs

Trilivy is built around Metabolic Synchronization®, a clinical framework that targets visceral fat reduction while protecting lean mass, pairing structured nutrition with independent Trilivy coaches and the Habits of Health® Transformational System. The system organizes healthy behaviors into six areas: Healthy Weight, Healthy Eating and Hydration, Healthy Movement, Healthy Sleep, Healthy Mind, and Healthy Surroundings. These habits work to build change through small, repeatable micro-habits practiced within each, paired with independent coach support designed to sustain progress beyond the initial plan.

Trilivy’s proprietary MetaVantage Reset Formula combines clinically studied, heat-treated postbiotic Bifidobacterium lactis CECT 8145, which helps support reduced waist circumference*, with choline for normal lipid/fat metabolism support, and chromium picolinate to help maintain healthy insulin function.

*Pedret, A., R.M. Valls, L. Calderon-Perez, et al. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond). 2019;43(9):1863- 1868. doi: 10.1038/s41366-018-0220-0.

Key Facts:

  • A peer-reviewed trial of the Reset 5 & 1 Plan documented a 14% reduction in visceral fat and 98% of lean mass retained at 16 weeks*

“The six areas targeted by the Habits of Health® system reflect just how much metabolic outcomes depend on daily life outside the plate. Micro-habits built into each of these areas, paired with coach support, carry individuals from an initial reset into a lasting shift surrounding how the body regulates weight and energy,” Jonnalagadda said.

FAQs

Question: What are the signs of poor metabolic health?
Answer: Poor metabolic health often surfaces as excess weight, low energy, and shifts in body composition not captured by body weight alone. Because visceral fat and lean mass changes happen internally, they may go unnoticed until symptoms like fatigue, slower recovery, or plateaued progress make the underlying dysfunction more visible.

Question: Can metabolic dysfunction be reversed?
Answer: Reversal is possible when structured nutrition, consistent habit formation, and coach support work together to restore balance between energy use, fat burn, and muscle preservation. Individual results vary.

Question: Does body weight alone tell you if you are metabolically healthy?
Answer: No. Body weight does not separate visceral fat from lean mass. In a 16-week clinical trial, individuals on the Reset 5 & 1 Plan retained 98% of lean mass and reduced visceral fat 14%. These results were not captured by weight alone.*

* Trilivy™ recommends that you contact your healthcare provider before starting and throughout your weight loss journey.

* Arterburn LM, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obesity Science & Practice. 2019. https://onlinelibrary.wiley.com/doi/10.1002/osp4.312. In a clinical study, individuals on the Reset 5 & 1 Plan experienced a reduction of 14% visceral fat and 98% of lean mass was retained at 16 weeks. 

¹ KRC Research, Metabolic Health in America Survey, 2025.

About Medifast and Trilivy
Medifast (NYSE: MED) is the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy. Designed to address the challenges of metabolic dysfunction, the company’s holistic approach integrates science-backed plans and products, personal 1:1 coaching, a supportive community, and behavioral science support to develop healthy habits.
Driven to improve metabolic health through advanced science and comprehensive behavioral support, Medifast has introduced Metabolic Synchronization®, a breakthrough science that targets metabolic dysfunction through a comprehensive system focused on fat loss, lean mass preservation, and long-term health. Trilivy’s comprehensive three-phase metabolic health system is designed to help people reset their metabolism, refine their health, and renew their lives. By integrating science, coaching, and healthy habits into a single approach, Trilivy helps people look, feel, and live better.
Backed by more than 45 years of clinical heritage, Medifast continues to advance its mission of lifelong transformation through metabolic science and human connection™. For more information, visit trilivyhealth.com and medifastinc.com.

CONTACT: Sarah Evans, CEO
Zen Media
sarah@zenmedia.com

  • In contact center AI, the recommendation an agent sees is not the most important asset. The key asset is the record of what agents accept, ignore, or change and whether anyone acts on it after go-live.
  • Agent assist surfaces the specific answer inside a live conversation, drawn from the company’s knowledge base, and stays useful only if it keeps learning from real calls.
  • Automated quality monitoring reviews every interaction instead of a sample, scoring both hard skills (compliance, accuracy) and soft skills (empathy, de-escalation).
  • Coaching and training optimization turns that quality signal into targeted practice aimed at the specific gaps the data surfaced.
  • CX insights aggregate what every interaction reveals and feed it back into the knowledge base, routing and training, so the operation compounds instead of drifting.

Vancouver, BC, Oct. 01, 2026 (GLOBE NEWSWIRE) — In the context of contact center AI, a recommendation engine is only as good as what happens to it over time, as products change, policies shift and the reasons customers call evolve. The value lies in the record of what agents do with each recommendation, including what they accept, ignore and modify, and whether anyone owns that loop once the launch team has moved on. TELUS Digital operates the full AI value chain with enterprises, helping them train, build, run and protect AI, and, distinctly, operates AI-powered contact center solutions. The company has outlined the four AI capabilities that support agents across a contact center interaction, and why the connections between them determine whether the customer experience delivery is effective.

Erin Walker, Global Vice President of CX AI, Business & Delivery at TELUS Digital, said, “Agents do their best work when the technology around them removes friction and feeds them accurate information at the moment they need it, instead of adding another screen to watch. When live guidance, quality review and coaching all run as separate systems, agents end up managing the tools instead of the conversation. The goal is for those systems to share what they know about an interaction, so an agent isn’t re-explaining context the technology already captured three steps earlier.”

KEY FACTS

  • TELUS Digital operates the full AI value chain with enterprises, spanning training, building, running and protecting AI, through its products and a deep technology-partner ecosystem.
  • TELUS Digital both operates contact centers and builds enterprise AI, including the Fuel iX™ platform.
  • Fuel iX™ is TELUS Digital’s proprietary enterprise AI platform and suite of products for clients to manage, monitor, and maintain generative AI across the enterprise.
  • Fuel iX Agent Trainer has helped accelerate agent proficiency by up to 50%.
  • In a TELUS Digital deployment of Fuel iX Agent Trainer and Agent Quality Insights, 100% of contact center interactions were automatically analyzed to identify coaching opportunities, improving coaching efficiency by 26%.

The Four Capabilities That Support Agents

Four AI capabilities support agents across a contact center interaction: agent assist that guides a live call, automated quality monitoring across every interaction, coaching that acts on what monitoring surfaces and CX insights that feed the whole operation. 

1. Agent Assist Puts the Right Answer in Front of the Agent

Real-time agent assist listens to a live conversation and surfaces the specific answer an agent needs at that moment, drawn from the organization’s knowledge base. Agent assist does this in place of traditional search that returns a wall of articles for the agent to read mid-call. That means the customer gets an answer right away instead of a hold while the agent reads. But “the right answer” is not fixed at launch. It has to stay accurate as products and policies change, which depends on capturing what agents accept, ignore and modify, and updating the underlying knowledge on that signal. Without updates, an agent assist tool might surface a promotion that has already ended or an outdated return policy, and the agent passes that wrong information to the customer with full confidence. 

2. Automated Quality Monitoring Reviews Every Call, on Hard Skills and Soft Skills

Traditional quality programs sample a small percentage of calls and score them after the fact. Automated quality monitoring reviews every interaction instead of a fraction and it evaluates both dimensions of a call that are important. This includes hard skills like compliance and accuracy, and soft skills like empathy, tone and de-escalation. Reviewing full-coverage data instead of a sample means a coaching pattern that shows up in a small share of calls that stays visible rather than disappearing into a rounding error. The result is a specific, evidence-based picture of where each agent is strong and where they need support to optimize coaching and training opportunities.

3. Coaching and Training Optimization Turns the Signal Into Targeted Practice

A quality signal only creates value if someone or something acts on it. Coaching and training optimization takes the skill gaps that quality monitoring surfaces and turns them into targeted practice, so agents work on the specific weaknesses the data identifies rather than sitting through a blanket refresher. Fuel iX Agent Trainer supports this with AI-driven voice and chat simulations that let agents rehearse the exact scenarios they struggle with in a risk-free practice environment with immediate feedback. In a TELUS deployment of Agent Trainer, that approach accelerated agent proficiency by up to 50% and improved CSAT by 18%. A quality score turns into a better customer conversation when coaching is guided by data.

4. CX Insights Turn Every Interaction Into Fuel for the Whole Operation

The final stage closes the loop. Individually, each capability improves one moment in the agent’s day. Aggregated, every interaction reveals information about what customers are asking, where answers are missing and where agents are getting stuck. Fed back into the system, those insights update the knowledge base that the agent assist draws from, refine how calls are routed and sharpen what coaching prioritizes next. When insights flow back to the start of the loop, the answer an agent surfaces next month improves on the one they surfaced today because the operation is continuously learning.

Connecting these four capabilities so they share what each one learns is a continuous delivery task that runs for the life of the deployment.

Frequently Asked Questions

Question: Why does real-time agent assist need to keep learning after go-live?
Answer: Products launch, policies change and the reasons customers call shift month to month. An agent assist tool that was accurate at launch falls behind as the business changes around it. Keeping it accurate means capturing what agents do with its suggestions and updating on that signal, so that it continues to evolve with the business and ensures the answer it surfaces stays current.

Question: What is the difference between automated quality monitoring on hard skills and soft skills?
Answer: Hard skills are the objective, verifiable parts of a call, such as compliance steps and factual accuracy. Soft skills are the human dimensions, such as empathy, tone and how well an agent de-escalates a frustrated customer. Reviewing both across every interaction, rather than a sampling, gives supervisors a complete picture of agent performance and surfaces coaching moments that a compliance-only score would miss.

Question: Can one partner connect live-call support, quality monitoring and coaching so they work together?
Answer: Connecting these capabilities so they share interaction data is an orchestration and delivery challenge rather than a single-product one. TELUS Digital works with contact center teams on that integration across its products, including the Fuel iX™ platform, and its technology-partner ecosystem.

Question: Where does an implementation partner add value in connecting these AI capabilities?
Answer: The value is less in any single tool and more in making the capabilities work as one system. TELUS Digital operates the full AI value chain with enterprises, training, building, running and protecting AI, which means helping brands deploy, implement, optimize and orchestrate these capabilities and stand behind the result, rather than handing over a set of disconnected tools.

About TELUS Digital

TELUS Digital crafts unique and enduring experiences for customers and employees and creates future-focused digital transformations that deliver value for our clients. We are the brand behind the brands. Our global team members are both passionate ambassadors of our clients’ products and services and technology experts resolute in our pursuit to elevate their end customer journeys, solve business challenges, mitigate risks, and drive continuous innovation. Our portfolio of end-to-end, integrated capabilities include customer experience management, digital solutions, such as cloud solutions, AI-fueled automation, front-end digital design and consulting services, AI & data solutions, including computer vision, and trust, safety and security services. Fuel iXTM is TELUS Digital’s proprietary platform and suite of products for clients to manage, monitor and maintain generative AI across the enterprise, offering both standardized AI capabilities and custom application development tools for creating tailored enterprise solutions.

Powered by purpose, TELUS Digital leverages technology, human ingenuity and compassion to serve customers and create inclusive, thriving communities in the regions where we operate around the world. Guided by our Humanity-in-the-Loop principles, we take a responsible approach to the transformational technologies we develop and deploy by proactively considering and addressing the broader impacts of our work. Learn more at: telusdigital.com.

CONTACT: Sarah Evans, CEO
Zen Media
sarah@zenmedia.com

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Oceanic Iron Ore Corp. (TSX-V: FEO; OTCQX: FEOVF), a mineral resource company, has qualified to trade on the OTCQX® Best Market. Oceanic Iron Ore Corp. upgraded to OTCQX from the Pink Limited™ Market.

Oceanic Iron Ore Corp. begins trading today on OTCQX under the symbol “FEOVF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws.

Trading in non-U.S. North American securities on OTC Markets reached $23.4 billion in the second quarter of 2026, representing an 88.25% increase over Q2 2025. OTC Markets recorded $453.34 billion in total dollar volume in the first half of the year. Canada ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Oceanic Iron Ore Corp.
Oceanic is focused on the development of its Ungava Bay iron ore properties in Nunavik, Québec. The properties comprise three project areas: Hopes Advance, Morgan Lake and Roberts Lake, with the lead asset being Hopes Advance. The three properties cover over 300 kilometres of iron formation and are located within 20 – 50 km of tidewater.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company”) is pleased to report assay results from hole BR26-007, the first hole of the Company’s 2026 drill program at its 100%-owned Birch Copper-Gold Project (“Birch”), located approximately 65 kilometres northeast of Burwash Landing, Yukon. Drilled as an approximately 200-metre step-out east along strike from hole BR25-003, BR26-007 intersected multiple near-surface skarn horizons, including 23.5 metres grading 0.48 grams per tonne (“g/t”) gold, 0.11% copper and 1.47 g/t silver from 39.5 metres downhole, extending the drilled strike length of near-surface mineralized skarn at Birch to approximately 1 kilometre.

Highlights

  • 23.5 metres (“m”) of 0.48 g/t gold (“Au”), 0.11% copper (“Cu”) and 1.47 g/t silver (“Ag”) from 39.5 m in an approximately 200 m step-out east of BR25-003, extending the drilled strike length of near-surface mineralized skarn to approximately 1 kilometre.
  • Multiple stacked skarn horizons in the upper part of the hole support the interpretation of a broader prospective stratigraphic package east of the previous drilling.
  • Mineralization is hosted in interlayered schist, marble/limestone and skarn, with chalcopyrite and pyrrhotite logged in the stronger gold-copper mineralized intervals.
  • An intercept of 0.8 m of 12.1 g/t Au and 2.84 g/t Ag from 261.0 m was drilled within an altered schist-skarn sequence at depth, indicating gold potential below the near-surface horizons.

“We are pleased that BR26-007 has extended the drilled footprint at Birch to approximately 1 kilometre in length, demonstrating that near-surface skarn gold and copper mineralization continues east along strike,” says Jim Coates, CEO of Yukon Metals. “The shallow skarn horizons remain our focus, while the deeper high-grade gold interval, intrusive relationships and mapped intrusion to the south provide additional vectors as we interpret the full 2026 dataset and plan follow-up work.”

Drill Results, Geology and Eastern Extension of the Birch Skarn System

BR26-007 was collared approximately 200 m east along strike from BR25-003 to test the continuation of the skarn-bearing stratigraphy identified in the Company’s inaugural drill program (Figure 1). The hole intersected multiple mineralized horizons in its upper 65 m, extending the drilled strike length of near-surface mineralized skarn at Birch to approximately 1 kilometre.

Figure 1
Figure 1- Plan map of the Birch project showing 2025 and 2026 drill collars, the approximately 1-kilometre drilled strike extent of near-surface mineralized skarn, and the location of BR26-007 approximately 200 m east of BR25-003.

Near the top of the hole, BR26-007 intersected 7.5 m grading 0.16 g/t Au, 0.04% Cu and 1.78 g/t Ag from 7.0 m, hosted in a mixed sequence of schist, skarn, intrusive and carbonate-bearing rocks.
Further downhole, the hole intersected 23.5 m grading 0.48 g/t Au, 0.11% Cu and 1.47 g/t Ag from 39.5 m. This interval includes 13.5 m grading 0.71 g/t Au, 0.17% Cu and 1.78 g/t Ag from 49.5 m, which in turn includes:

  • 1.3 m grading 4.05 g/t Au, 0.15% Cu and 2.45 g/t Ag from 49.5 m, in marble/limestone with chloritized skarn and blebby to disseminated chalcopyrite; and
  • 4.2 m grading 0.82 g/t Au, 0.45% Cu and 4.37 g/t Ag from 58.8 m, in strongly chlorite-altered skarn with pyrrhotite and chalcopyrite.

Table 1- Highlighted assay results from drill hole BR26-007.

Hole From (m) To (m) Length
(m)
Au (g/t) Cu (%) Ag (g/t) CuEq*
(%)
BR26-007 7   14.5   7.5   0.16   0.04   1.78   0.20  
and 39.5   63   23.5   0.48   0.11   1.47   0.58  
incl.   49.5   63   13.5   0.71   0.17   1.78   0.87  
incl.   49.5   50.8   1.3   4.05   0.15   2.45   4.02  
incl.   58.8   63   4.2   0.82   0.45   4.37   1.27  
and 261   261.8   0.8   12.10   0.02   2.84   11.54  
 

Reported intervals are downhole core lengths; true widths have not yet been determined. *Copper equivalent (CuEq %) values have been calculated using the formula: CuEq % = Cu % + (Au g/t × 0.95) + (Ag g/t × 0.0095), based on metal prices of US$4.00/lb Cu, US$3,000/oz Au and US$40/oz Ag. Recovery factors of 92% for copper, 80% for gold and 60% for silver were assumed based on a review of comparable projects. No metallurgical test work has been completed at Birch.

The 2026 drilling builds on the Company’s inaugural 2025 exploration program, which tested a gold-copper soil anomaly measuring 1.4 kilometres long and up to 400 m wide, coincident with carbonate-bearing stratigraphy and cross-cutting intrusive rocks. That drilling confirmed a mineralized skarn system developed within interlayered schist and marble cut by multiple phases of intrusive dykes (see September 3, 2025 news release ).

BR25-003, the easternmost hole of the 2025 program, was drilled approximately 300 m northeast of BR25-001 and intersected 47.4 m grading 0.43 g/t Au from 26.6 m (see December 8, 2025 news release). BR26-007 extends mineralized skarn a further 200 metres east of BR25-003.

BR26-007 intersected numerous porphyritic intermediate intrusive dykes throughout the hole, including immediately above the shallow mineralized package beginning at 39.5 m (Figure 2). The 2025 drilling showed a similar relationship, with mineralization locally concentrated along the margins of granodiorite and feldspar-porphyry dykes. These observations support the Company’s interpretation that intrusive emplacement played an important role in the development and distribution of skarn alteration and mineralization at Birch.

Figure 2
Figure 2- Cross-section through BR26-007 and adjacent drilling showing interpreted geology, principal skarn horizons and Cu equivalent assay intervals. Copper equivalent (CuEq %) values have been calculated using the formula: CuEq % = Cu % + (Au g/t × 0.95) + (Ag g/t × 0.0095), based on metal prices of US$4.00/lb Cu, US$3,000/oz Au and US$40/oz Ag. Recovery factors of 92% for copper, 80% for gold and 60% for silver were assumed based on a review of comparable projects. No metallurgical test work has been completed at Birch.

Mineralization in the upper portion of BR26-007 occurs across multiple horizons within interlayered schist, marble/limestone and skarn. Higher gold and copper grades correlate with more intense skarn alteration and increased sulphide content, including logged chalcopyrite and pyrrhotite (Figure 3). The recurrence of mineralized skarn within similar stratigraphy east of BR25-003 expands the known drilled footprint of the system and supports continued exploration along strike.

Deeper in the hole, BR26-007 returned a narrow interval grading 12.1 g/t Au and 2.84 g/t Ag from 261.0 m within an altered schist-skarn sequence immediately adjacent to a logged fault zone (Figure 4). The association of this higher-grade gold with the fault, together with sulphide-bearing veinlets in the surrounding altered rocks, suggests that structural controls may also influence the distribution of mineralization at Birch.

The 2026 exploration program at Birch included approximately 2,600 m of diamond drilling in six holes, building on the 1,687 m completed during the Company’s inaugural 2025 drill program. The 2026 drilling was designed to expand the skarn system along strike and at depth, and to test additional targets developed from geological, geochemical and geophysical data. Assays are pending for the remaining 2026 drill holes.

BR26-007 is the first hole from the 2026 program for which assays have been received. Results from the remaining holes will be released as assays are received, validated through the Company’s quality assurance and quality control (“QA/QC”) procedures and interpreted in the context of the evolving Birch geological model.

The Company also completed 12.7 line-kilometres of induced polarization (“IP“) surveying across the broader Birch target area, together with mapping and prospecting over and around an intrusive body located approximately 2 kilometres south of the drill area. This work was undertaken to better characterize the intrusion, its associated alteration and mineralization, and its potential relationship to the broader mineralizing system at Birch.

Results from additional 2026 drill holes, together with ongoing interpretation of the drilling, IP, mapping and prospecting datasets, will be used to refine the geological model and guide future exploration at Birch.

Figure 3

Figure 3- Core photograph from the upper mineralized interval in BR26-007, showing skarn-altered carbonate with sulphide mineralization associated with the 23.5-m interval grading 0.48 g/t Au, 0.11% Cu and 1.47 g/t Ag from 39.5 m.

Figure 4

Figure 4- Core photograph of the deeper high-grade gold interval in BR26-007, which returned 0.8 m grading 12.1 g/t Au and 2.84 g/t Ag from 261.0 m, immediately adjacent to a logged fault zone.

Table 2- Drill collar information for BR26-007, NAD83 UTM Zone 7.

Hole Easting Northing Elevation (m) Azimuth Dip EOH (m)
BR26-007 648792 6859169 1455 0 -70 466.00


QA/QC

All diamond drill core from the 2026 program at Birch was logged, photographed, and sawn in half using a diamond blade core saw. One half of the core was submitted for geochemical analysis, while the other half was retained in secure storage for reference. Sampling intervals were determined based on geological boundaries and typically ranged 0.3- 1.5 metres. Control samples comprised approximately 10% of all samples submitted, including certified reference standards, analytical blanks, field duplicates, and preparation duplicates.

QA/QC results were reviewed in real time, and all data has been verified as meeting acceptable thresholds for accuracy, precision, and contamination before inclusion in this news release.

Drill core samples were sent to SGS Canada Inc. (“SGS”) for sample preparation and analysis in Burnaby, British Columbia. Samples were prepared by crush to 75% passing 2mm, 250g split pulverised better than 85% passing 75 microns (PRP89). Pulp samples were analysed for 40 elements by four acid digestion and ICP-AES/ICP-MS (GE_ICP40Q12). All samples were analyzed for gold by fire assay and AAS with a 50g nominal sample weight (GE_FAA50V5). Overlimit gold values, >10 g/t Au, were analyzed with fire assay with gravimetric finish (GO_FAG50V). Samples were then sent to SGS’s Lakefield facility for portable near-infrared scanning of the coarse crush split to characterize alteration mineralogy.

About Birch

Birch is a 7,000-hectare copper-gold exploration property located in western Yukon, approximately 65 kilometres northeast of Burwash Landing. The 100%-owned, helicopter-accessed property represents an emerging copper-gold exploration opportunity within Yukon Metals’ broader Yukon portfolio, with multiple target areas identified across the project. Exploration to date has outlined skarn-style copper-gold mineralization, while geological, geochemical, and geophysical work suggests the potential for additional epithermal and porphyry-style mineralized systems.

Building on the 2025 program, which included 1,685 metres of HQ diamond drilling in 6 holes and established a broad copper-gold skarn footprint at Birch, Yukon Metals’ 2026 exploration program included approximately 2,600 m of additional diamond drilling, 12.7 line-kilometres of IP surveying, and follow-up geological mapping and rock sampling across priority target areas.

About Yukon Metals Corp.

The Yukon Metals portfolio was built on more than 30 years of prospecting by the Berdahl family, the prospecting team behind Snowline Gold Corp.’s portfolio. The portfolio consists primarily of copper-gold projects, with substantial exposure to tungsten. Additional portfolio assets include gold, silver and lead-zinc polymetallic properties.
The Company is well financed and led by an experienced Board of Directors and management team across technical and financial disciplines. Yukon Metals is focused on fostering sustainable growth and prosperity within Yukon’s local communities, while simultaneously enhancing stakeholder value. The Company’s strategy centers around inclusivity and shared prosperity, offering both community members and investors the chance to contribute to, and benefit from, its ventures.

The Yukon

The Yukon Territory is an underexplored and minerally endowed district with a mining history dating back to the Klondike Gold Rush of 1898. With a progressive permitting regime, geopolitical stability and supportive government, it is well positioned to foster the next generation of mines. The Yukon is host to a highly experienced and conscientious local workforce, fostered by a long culture of exploration coupled with deep respect for the land. Recent major discoveries with local roots such as Snowline Gold Corp.’s Rogue Project – Valley Discovery, demonstrate the Yukon’s potential to generate fresh district-scale mining opportunities.

Qualified Person

The technical content of this news release has been reviewed and approved by Helena Kuikka, P.Geo., VP Exploration for Yukon Metals and a Qualified Person (as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects).

“ON BEHALF OF THE BOARD OF YUKON METALS CORP.

“Jim Coates”

Jim Coates, CEO
Email: jimcoates@yukonmetals.com

For additional information, please contact:
Lindsay Wilson
VP, Investor Relations & Communications
Email: lindsaywilson@yukonmetals.com
Phone: 1 (778) 996-2192

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains certain forward-looking information, including information regarding the interpretation, geological significance, potential continuity and extent of mineralization at Birch; the interpretation of the relationship between skarn mineralization, intrusive rocks and structural features; the potential significance of the approximately 1 kilometre drilled strike extent of near-surface mineralized skarn; continued exploration of shallow skarn horizons at Birch; the integration of drilling results with geological mapping, geochemistry and geophysical data; the potential to refine and identify future exploration targets at Birch; and the Company’s future exploration plans and intentions. Wherever possible, words such as “may”, “will”, “should”, “could”, “can”, “continue”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential”, or the negative or other variations of these words, or similar words or phrases, have been used to identify forward-looking information. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking information involves significant risks, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from those discussed or implied in the forward-looking information. Such factors include, among other things: risks and uncertainties relating to Birch and other properties not being prospective copper-rich, gold-rich or silver-rich geological systems; rock samples analysed not being representative of overall mineralization; the required assumptions of completed drilling and sampling programs, including the 2026 and 2025 programs; the timing of completed assay results from the 2026 program; the ability to refine the geological model and guide future exploration at Birch based on results from additional 2026 drill holes, IP, mapping and prospecting datasets; not having significant scale and a lack of economic grade minerals; the Yukon not having the potential to generate fresh district-scale mining opportunities; and other risks and uncertainties. See the section entitled “Risk Factors” in the Company’s listing statement dated May 30, 2024, available under the Company’s profile on SEDAR+ at www.sedarplus.ca for additional risk factors. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking information. Although the forward-looking information contained in this news release is based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with the forward-looking information. The forward-looking information is made as of the date of this news release, and the Company assumes no obligation to update or revise the information to reflect new events or circumstances, except as required by law.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/805ef77d-2724-4472-a63e-1e125e2c78e1
https://www.globenewswire.com/NewsRoom/AttachmentNg/c0555a14-e27b-4e5b-90e2-e16343b18f67
https://www.globenewswire.com/NewsRoom/AttachmentNg/f4751275-40e5-400b-ac22-9e5f45270d1e
https://www.globenewswire.com/NewsRoom/AttachmentNg/18b5ca62-e4d7-4676-84ed-f2e2e103b660

Plasma torch system and auxiliary equipment undergoing final adjustments and commissioning to confirm specification compliance

MONTREAL, Oct. 01, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or the “Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, today confirmed that installation of the Company’s 4.5 MW plasma torch system for a U.S. defense and aeronautics research facility, has been completed. The system and its auxiliary components are now undergoing final adjustments to ensure specification compliance.

As announced previously, PyroGenesis signed a contract valued at approximately $4.13 million (US$3.13 million) with a U.S. corporation who regularly serves as a prime contractor for the U.S. government as well as for public and private customers in the aeronautics and related industries. The contract is for the design and build of a 4.5 MW plasma torch system and related peripherals. The project is the first of two large-scale plasma torch system projects for this client, who subsequently ordered a 20 MW plasma torch, announced October 21, 2024. The 20 MW torch system, with a signed budget of $27 million (US$19.6 million), is expected to be the largest plasma torch ever produced commercially, based on the Company’s own research.

4-5MW

Image: PyroGenesis’ 4.5 MW plasma torch

The 4.5 MW plasma torch system was subsequently delivered to the client [announced January 27, 2026], pending completion of the client’s facility to enable installation. Over the past few weeks, the system and related peripheral components were installed. Live pre-operational startup and testing of the plasma torch have commenced.

Once fully operational, and all specification adjustments have been completed, the plasma torch is expected to operate within an extreme-temperature test tunnel, generating the ultra-high-temperature conditions required to expose materials and scale models to extreme thermal environments and assess their performance for aeronautics applications. For reference, a 4.5 MW plasma torch is equivalent to the average concurrent electricity demand of approximately 3,750 average U.S. homes (based on an average U.S. household’s continuous demand of 1.2kW1).

The client is a leading center for innovation, technology development, and testing in support of critical defense, military, and aeronautics applications. Its world-class scientific community includes internationally recognized experts whose collective contributions span numerous landmark achievements in U.S. aeronautics. The client’s facilities house unique full-scale test conditions considered essential to U.S. national security.

“This announcement marks an important milestone in the deployment of our high-power plasma technology for advanced aeronautics testing,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “With the torch now installed, the system will proceed through commissioning before entering its intended operational phase, where the system is expected to support the client’s specialized test programs by providing a controlled, high-power plasma heat source capable of generating exceptionally demanding thermal conditions. This installation also represents an important step in our ongoing relationship with the client, which has already ordered a 20 MW plasma torch. The 20 MW system represents the next major scale-up in plasma power and, based on our research, is expected to be the largest plasma torch ever produced commercially.”

Today’s announcement complemented other advancements to the Company’s high-powered plasma torch business line that the Company has previously announced. The following is a short summary of two of the more prominent projects that are currently underway:

  1. Constellium:

    As previously announced (press release dated August 5, 2025), PyroGenesis signed an industrial implementation contract with Constellium, one of the world’s largest aluminum transformation and recycling companies, for the sale of plasma torch technology and related peripheral components, for use in a Constellium aluminum remelting furnace. This followed a previous announcement (press release dated April 10, 2024) detailing a collaboration agreement whereby Constellium stated its intention to use PyroGenesis plasma torches as potential replacement heating sources in Constellium’s aluminum cast houses.

    More recently, the Company announced [press release March 6, 2026] successful completion of the system and commencement of the delivery and installation phase.

    The Company today reports that the system has been operating successfully since early June 2026 within a furnace at a Constellium manufacturing plant in France. Since that time, the furnace has been successfully producing aluminum, using PyroGenesis’ plasma torch system as the furnace heat source.

    The system will continue operating and producing aluminum during October, at which point the first phase of the collaboration agreement will be completed. At that point, the next phase in the collaboration agreement will be discussed between Constellium and PyroGenesis.

  2. Norsk Hydro ASA

    As previously announced (press release dated February 24, 2025), PyroGenesis signed a €1.63 million (CA$2.4 million) contract with Norsk Hydro ASA (“Hydro”), a Norway-based aluminum and renewable energy company that, since its founding in 1905, has become one of the largest aluminum producers in the world and one of the most respected and influential leaders in heavy industry. The contract with PyroGenesis is to test plasma technology as one of the ways to replace fossil fuels with renewable alternatives in its aluminum casthouses. This contract followed Hydro publicly announcing (in January 2024) its stated goal to achieve net-zero emissions across the entire aluminum value chain by 2050, including their intention to test plasma technology in their test center in Sunndal Norway.

    The Company today reports that the development of the plasma torch system for Hydro has been completed, and the system and related components are expected to arrive at Hydro’s Sunndal facility during Q4 2026. The plasma torch system will then be installed in an aluminum furnace, with start-up and commissioning expected to be completed during Q1 2027.

    Hydro’s Sunndal facility is the largest and most modern primary aluminum plant in Europe. The facility, which also houses remelting, casthouse, and research and development activities, produces over 400,000 tonnes of primary aluminum, 500,000 tonnes of casthouse products, and 80,000 tonnes of anodes annually.2

About PyroGenesis Inc.

PyroGenesis leverages 35 years of plasma technology leadership to deliver advanced engineering solutions to energy, propulsion, destruction, process heating, emissions, and materials development challenges across heavy industry and defense. Its customers include global leaders in aluminum, aerospace, steel, iron ore, utilities, environmental services, military, and government. From its Montreal headquarters and local manufacturing facilities, PyroGenesis’ engineers, scientists, and technicians drive innovation and commercialization of energy transition and ultra-high temperature technology. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified, with ISO certification maintained since 1997. PyroGenesis’ shares trade on the TSX (PYR), OTCQX (PYRGF), and Frankfurt (8PY1) stock exchanges.

Cautionary and Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by PyroGenesis as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the risk factors identified under “Risk Factors” in PyroGenesis’ latest annual information form, and in other periodic filings that it has made and may make in the future with the securities commissions or similar regulatory authorities, all of which are available under PyroGenesis’ profile on SEDAR+ at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect PyroGenesis. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. PyroGenesis undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQX Best Market accepts responsibility for the adequacy or accuracy of this press release.

For further information contact ir@pyrogenesis.com or visit http://www.pyrogenesis.com

1 https://www.eia.gov/tools/faqs/faq.php?id=97&t=7

2 https://www.hydro.com/en/global/about-hydro/hydro-worldwide/europe/norway/sunndal/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/adc0db89-dc10-4c43-8bed-e7f742ab1fe4

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.